Piperidine, 3,4-didehydro-2,2,4,6,6-pentamethyl- | 63867-75-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Piperidine, 3,4-didehydro-2,2,4,6,6-pentamethyl-
• 英文别名: 2,2,4,6,6-pentamethyl-1,3-dihydropyridine
• CAS: 63867-75-4
• 化学式: C₁₀H₁₉N
• 分子量: 153.26
• InChiKey: AXBXRPOZGNYKMV-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.6
• 重原子数：
  11
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

文献信息

• [EN] SUBSTITUTED 1,5-NAPHTHYRIDINES OR QUINOLINES AS ALK5 INHIBITORS<br/>[FR] 1,5-NAPHTYRIDINES OU QUINOLÉINES SUBSTITUÉES EN TANT QU'INHIBITEURS D'ALK5
  申请人：THERAVANCE BIOPHARMA R&D IP LLC

  公开号：WO2021102468A1

  公开（公告）日：2021-05-27

  The present disclosure provides inhibitors of activin receptor-like kinase 5 (ALK5). Also disclosed are methods to modulate the activity of ALK5 and methods of treatment of disorders mediated by ALK5.

  本公开提供了激活素受体样激酶5（ALK5）的抑制剂。还公开了调节ALK5活性的方法和通过ALK5介导的疾病的治疗方法。
• COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF PARASITIC DISEASES
  申请人：BIGGART Agnes

  公开号：US20150175613A1

  公开（公告）日：2015-06-25

  The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

  本发明提供了Formula A的化合物：或其药学上可接受的盐、互变异构体或立体异构体，其中变量如本文所定义。本发明还提供了包含这种化合物的药物组合物，并使用这种化合物治疗、预防、抑制、改善或根除由寄生虫引起的疾病的病理学和/或症状学的方法，如利什曼病、人类非洲锥虫病和光照病。
• [EN] SULFONATED PHENOLS WITH NITROPHENOLS AS POLYMERIZATION INHIBITORS<br/>[FR] PHENOLS SULFONES AVEC NITROPHENOLS COMME INHIBITEURS DE POLYMERISATION
  申请人：CHEMTURA CORP

  公开号：WO2006036274A1

  公开（公告）日：2006-04-06

  Disclosed herein is a method for inhibiting the premature polymerization and the polymer growth of ethylenically unsaturated monomers comprising adding to said monomers an effective amount of a combination of (A) at least one inhibitor that is a sulfonated phenol of the formula (I): wherein (1) R2 is selected from the group consisting of hydrogen and hydrocarbyl; and (2) R1 and R3 are independently selected from the group consisting of hydrogen and SO3H, provided that at least one of R1 and R3 is SO3H; (B) at least one inhibitor that is a nitrophenol; and, optionally, (C) an inhibitor selected from the group consisting of nitroxyl compounds and nitrosoanilines; and (D) an amine.

  本文公开了一种抑制乙烯基不饱和单体的过早聚合和聚合生长的方法，包括向该单体中添加以下组合物的有效量：（A）至少一种为公式（I）的磺化酚抑制剂，其中（1）R2选自氢和烃基组成的群体；（2）R1和R3独立地选自氢和SO3H组成的群体，但其中至少一个为SO3H；（B）至少一种为硝基酚的抑制剂；以及可选地，（C）从硝基氧化物化合物和硝基苯胺组成的群体中选择的抑制剂；和（D）胺。
• Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants
  申请人：Hideg Kalman

  公开号：US20070072912A1

  公开（公告）日：2007-03-29

  Compounds of the formula (I) and their pharmaceutically acceptable or technically applicable acid salts—where in the formula R 1 represents hydrogen, C (1-4) alkyl or C (1-4) alkoxy R 2 represents hydrogen, C (1-4) alkyl, carboxyl, C (1-4) alkoxycarbonyl, carboxamido, aryl or hetero-aryl R 3 represents hydrogen, C (1-4) alkyl, aryl-methylene, or aryl, Y is a valency bond, a straight or branched chain C (1-4) alkene, a carbonyl-amino-C (1-4) alkene, or a —S—(CH 2 ) m — group, where all alkene groups above may be spaced by an arylene group, n represents zero or the integer 1 m represents the integer 1, 2 or 3 Q represents hydrogen, hydroxyl or the oxygen radical (0) or together with the N atom of the adjacent ring forms a +N=O (oxoimmonium) group Z represents a single or double bond and their pharmaceutically acceptable or technically useful salts, processes for their preparation and their biological use as PARP inhibitors and antioxidants.

  公式（I）的化合物及其药学上可接受或技术上适用的酸盐——其中在公式中，R1代表氢，C（1-4）烷基或C（1-4）烷氧基；R2代表氢，C（1-4）烷基，羧基，C（1-4）烷氧羰基，羧酰胺基，芳基或杂环芳基；R3代表氢，C（1-4）烷基，芳基-亚甲基或芳基；Y是一个价键，一条直链或支链C（1-4）烯烃，一个羰基-氨基-C（1-4）烯烃，或一个—S—（CH2）m—基团，其中上述所有烯烃基团可以由一个芳基基团间隔；n代表零或整数1；m代表整数1、2或3；Q代表氢，羟基或氧基（0）或与相邻环的N原子一起形成+ N = O（氧代亚氨基）基团；Z代表单键或双键及其药学上可接受或技术上有用的盐，制备它们的过程以及它们作为PARP抑制剂和抗氧化剂的生物学用途。
• Compounds and compositions for the treatment of parasitic diseases
  申请人：NOVARTIS AG

  公开号：US10596175B2

  公开（公告）日：2020-03-24

  The present invention provides compounds of Formula A: or a pharmaceutically acceptable salt, tautomer, or stereoisomer, thereof, wherein the variables are as defined herein. The present invention further provides pharmaceutical compositions comprising such compounds and methods of using such compounds for treating, preventing, inhibiting, ameliorating, or eradicating the pathology and/or symptomology of a disease caused by a parasite, such as leishmaniasis, human African trypanosomiasis and Chagas disease.

  本发明提供了式 A 的化合物： 或其药学上可接受的盐、同系物或立体异构体，其中变量如本文所定义。本发明进一步提供了包含此类化合物的药物组合物以及使用此类化合物治疗、预防、抑制、改善或根除寄生虫引起的疾病（如利什曼病、人类非洲锥虫病和南美锥虫病）的病理和/或症状的方法。